Patents Assigned to Deciduous Therapeutics, Inc.
  • COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
    Publication number: 20250092078
    Abstract: Compounds for activating invariant natural killer T cells (iNKT) cells are provided. Compounds according to certain embodiments activate iNKT cells and induce an increase in the production of one or more cytokines, such as IFN?, IL-2, IL-4, IL-6 and TNF?. In some embodiments, activated iNKT cells are used to selectively reduce the presence of or eliminate inflammatory senescent cells, such as senescent cells having an inflammatory secretome (SASP). Methods for activating iNKT cells by contacting an iNKT cell with an amount of the subject compounds and selectively reducing the presence of or eliminating senescent cells with activated iNKT cells are also described. Compositions for practicing the subject methods are also described.
    Type: Application
    Filed: May 2, 2024
    Publication date: March 20, 2025
    Applicant: Deciduous Therapeutics, Inc.
    Inventors: Matthew DUNCTON, Thomas BOBINSKI, Ajit SHAH, Naze Gul AVCI, Abhijit KALE, Rachel HATANO, John GALLOWAY, Scott ARMSTRONG, Robin MANSUKHANI, Jasmine DENNY
  • Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells
    Patent number: 12037357
    Abstract: Compounds as depicted below and structural analogues thereof for activating invariant natural killer T cells (iNKT) cells are provided. Such compounds may be used to activate iNKT cells and induce an increase in the production of one or more cytokines, such as IFN?, IL-2, IL-4, IL-6 and TNF?. Activated iNKT cells may be used to selectively reduce the presence of or eliminate inflammatory senescent cells, such as senescent cells having an inflammatory secretome (SASP). Also provided are pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: July 16, 2024
    Assignee: Deciduous Therapeutics, Inc.
    Inventors: Matthew Duncton, Thomas Bobinski, Robin Mansukhani
  • COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
    Publication number: 20240025936
    Abstract: Compounds for activating invariant natural killer T cells (iNKT) cells are provided. Compounds according to certain embodiments activate iNKT cells and induce an increase in the production of one or more cytokines, such as IFN-?, IL-2, IL-4, IL-6 and TNF?. In some embodiments, activated iNKT cells are used to selectively reduce the presence of or eliminate inflammatory senescent cells, such as senescent cells having an inflammatory secretome (SASP). Methods for activating iNKT cells by contacting an iNKT cell with an amount of the subject compounds and selectively reducing the presence of or eliminating senescent cells with activated iNKT cells are also described. Compositions for practicing the subject methods are also described.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 25, 2024
    Applicant: Deciduous Therapeutics, Inc.
    Inventors: Matthew Duncton, Thomas Bobinski, Ajit Shah, Naze Gul AVCI, Abhijit Kale, Rachel Hatano, John Galloway, Scott Armstrong, Robin Mansukhani, Jasmine Denny